Search Videos by Topic or Participant
Browse by Series:

CancerTYPE ID and Next-Generation Sequencing

Insights From:F. Anthony Greco, MD, Sarah Cannon Cancer Center; Suresh S. Ramalingam, MD, Emory University
Published: Thursday, Aug 13, 2015


CancerTYPE ID (CTID) can help determine the tissue of origin and help to determine a tumor subtype, in conjunction with clinical and pathological assessments. Additionally, a prospective study of 444 patients, examined the utilization of CTID as a decision-making aid, notes F. Anthony Greco, MD.

In the study, results from CTID altered the treatment decision for 46% of patients, notes Greco. Some of these patients received additional molecular testing because of their diagnosis, to determine the presence of actionable mutations that could be treated with targeted therapy, particularly in adenocarcinoma of the lung, colon, and breast.

Another study evaluated the bioT3 program, which is a combination of the CTID molecular classifier and next generation sequencing plus (NGS+) with selected fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) staining, says Greco. This study assessed 465 patients with unclear or unknown primary cancer, with 27 distinct tumor types detected. 

Of the tumor types identified, the test uncovered 70 patients (15%) with non-small cell lung cancer. Of these patients, 51% harbored actionable molecular abnormalities determined by the NGS+ portion of the bioT3 platform. These abnormalities included KRAS (25.7%), KIT (21.4%), EGFR (8.6%), PIK3CA (7.1%), and BRAF (2.9%).
Slider Left
Slider Right


CancerTYPE ID (CTID) can help determine the tissue of origin and help to determine a tumor subtype, in conjunction with clinical and pathological assessments. Additionally, a prospective study of 444 patients, examined the utilization of CTID as a decision-making aid, notes F. Anthony Greco, MD.

In the study, results from CTID altered the treatment decision for 46% of patients, notes Greco. Some of these patients received additional molecular testing because of their diagnosis, to determine the presence of actionable mutations that could be treated with targeted therapy, particularly in adenocarcinoma of the lung, colon, and breast.

Another study evaluated the bioT3 program, which is a combination of the CTID molecular classifier and next generation sequencing plus (NGS+) with selected fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) staining, says Greco. This study assessed 465 patients with unclear or unknown primary cancer, with 27 distinct tumor types detected. 

Of the tumor types identified, the test uncovered 70 patients (15%) with non-small cell lung cancer. Of these patients, 51% harbored actionable molecular abnormalities determined by the NGS+ portion of the bioT3 platform. These abnormalities included KRAS (25.7%), KIT (21.4%), EGFR (8.6%), PIK3CA (7.1%), and BRAF (2.9%).
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x